Prosecution Insights
Last updated: November 20, 2026

William Y Lee, USPTO Patent Examiner

Listed by the USPTO as LEE, WILLIAM Y

Tech Center 1600 • Art Units: 1623 1626 1629

This examiner grants 48% of resolved cases

Analysis

LEE, WILLIAM Y is assigned to USPTO Tech Center 1600 and art unit 1623. The profile covers 714 resolved cases, with an allowance rate of 47.9% and a median of 1171 days to allowance. The interview lift is 34.3%.

The record reflects a docket where applicants may need sustained substantive engagement. The allowance rate supports careful claim positioning and evidence selection, while the positive interview lift makes examiner interviews a practical consideration when clarifying the technical distinction over the cited art. The median period indicates that prosecution planning should account for a lengthy timeline.

The leading companies are Sydnexis, Inc., Sage Therapeutics LLC, and Spruce Biosciences Inc. The leading firms are WILSON SONSINI GOODRICH & ROSATI, BakerHostetler, and Knobbe, Martens, Olson & Bear, LLP. Those associations may help counsel identify comparable matters for preparation.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Performance Statistics

47.9%
Allow Rate
-12.1% vs TC avg
802
Total Applications
+34.3%
Interview Lift
1171
Avg Prosecution Days
Based on 714 resolved cases, 2023–2026

Rejection Statute Breakdown

1.5%
§101 Eligibility
13.0%
§102 Novelty
45.0%
§103 Obviousness
21.2%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
17727519 Method of Treating Colorectal Cancers Using a PKC Inhibitor Final Rejection UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC.
18480409 CDK4/6 INHIBITORS AS A TREATMENT FOR CLONAL HEMATOPOIESIS Non-Final OA Washington University
18567952 PESTICIDALLY ACTIVE DIAZINE-AMIDE COMPOUNDS Non-Final OA SYNGENTA CROP PROTECTION AG
18201882 MULTIBIOTIC AGENTS AND METHODS OF USING THE SAME Non-Final OA Flagship Pioneering Innovations V, Inc.
18237705 COMPOSITIONS AND METHODS FOR IMPROVED TREATMENT OF PLATINUM-BASED CHEMOTHERAPEUTIC RESISTANT TUMORS Non-Final OA THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE
18684808 QUINACRINE AND DERIVATIVES THEREOF FOR TREATMENT OF VIRAL INFECTIONS Non-Final OA ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA
17923786 Uses and Formulations of Cannabinoids Non-Final OA ADD Advanced Drug Delivery Technologies Ltd.
18705084 PIPERIDINYL INDOLE DERIVATIVES, PREPARATION METHODS AND MEDICINAL USES THEREOF Non-Final OA JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD.
17874522 GLYCOLIC ACID PROTECTS AGAINST ISCHEMIC INSULTS Non-Final OA Individual inventor

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Who Appears Before This Examiner

Top companies before this examiner

Law firms appearing most often

Frequently Asked Questions

What is examiner William Y Lee's allowance rate?

47.9% of resolved applications examined by William Y Lee were allowed (714 resolved cases), compared with 51.0% across Art Unit 1623 over the last five years.

Does an interview help with examiner William Y Lee?

This examiner's interview lift is +34.3 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.

How long does examiner William Y Lee take to allow a patent?

Applications allowed by William Y Lee took 1,171 days on average from filing to allowance.

Which art unit does examiner William Y Lee work in?

William Y Lee examines applications in Art Unit 1623 in Tech Center 1600 (Biotechnology & Pharmaceuticals).

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month